Taxane‐platinum combination chemotherapy versus single agent platinum for the first‐line treatment of epithelial ovarian cancer
References
Additional references
Bookman MA. The addition of new drugs to standard therapy in the first‐line treatment of ovarian cancer. Annals of Oncology 2010;Suppl 7:vii211‐17.
Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta‐Analysis in Context (2nd edition). London: BMJ Publication Group, 2001.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C. Parkin DM. Cancer incidence and mortality worldwide. Avaialble from: http://globocan.iarc.fr.
Goldie JH. Modelling the process of drug resistance. Lung Cancer 2004;10(Suppl 1):S91–S96.
Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009;374(9698):1371‐82.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxal plus carboplatin versus standard chemotherapy with either single‐agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;260(9332):505‐15.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. A Cancer Journal for Clinicians 2008;58(2):71‐96.
Makatsoris T, Seiden MV. High‐dose therapy for ovarian carcinoma. The Oncologist 1997;2:330‐9.
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine 1996;334(1):1‐6.
Mouratidou D, Gennatas C, Michalaki V, Papadimitriou A, Andreadis CH, Sykiotis C, et al. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Anticancer Research 2007;27(1B):681‐5.
Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. Journal of Clinical Oncology 2000;18(1):106‐15.
Ozols RF. Maintenance therapy in advanced ovarian cancer: progression‐free survival and clinical benefit. Journal of Clinical Oncology 2003;12(13):2451‐3.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;24:2815‐34.
Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin‐paclitaxel versus cisplatin‐cyclophosphamide in women with advanced epithelial ovarian cancer: Three‐year results. Journal of the National Cancer Institute 2000;92(9):699‐708.
Quinn M, Babb B, Brock A, Jones J. Statistics of Cancer Trends in England and Wales. London: Her Majesty's Stationery Office (HMSO), 2001.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al. and the EUROCARE Working Group. EUROCARE‐3: survival of cancer patients diagnosed 1990–94—results and commentary. Annals of Oncology 2003;14(suppl 5):v61‐v118.
Shepherd JH. Revised FIGO staging for gynaecological cancer. British Journal of Obstetrics and Gynaecology 1989;96(8):889‐92.
Tuma RS. Ovarian cancer: is dose‐dense paclitaxel better than three‐weekly administration?. Oncology Times UK 2009;6(12):19‐20.
van der Burg ME, Boere IA, Berns PM. Dose‐dense therapy is of benefit in primary treatment of ovarian cancer: contra. Annals of Oncology 2011;22(Suppl 8):viii33‐viii39.
Vasey PA. “Dose dense” chemotherapy in ovarian cancer. International Journal of Gynecological Cancer 2005;15(Suppl 3):226–32.
